Comparative study of 2‐year outcomes for Hydrus or iStent inject microinvasive glaucoma surgery implants with cataract surgery. (4th February 2022)

• Record Type: Journal Article
• Authors: Holmes, David P.; Clement, Colin I.; Nguyen, Vuong; Healey, Paul R.; Lim, Ridia; White, Andrew; Yuen, Joshua; Lawlor, Mitchell
• Is Part Of: Clinical & experimental ophthalmology. Volume 50:Number 3(2022)
• Page Start: 303
• Page End: 311
• Publication Date: 2022-02-04
• Subjects: glaucoma -- Hydrus Microstent -- iStent inject -- minimally invasive glaucoma surgery; Ophthalmology -- Periodicals; 617.7
• DOI: 10.1111/ceo.14048
• Languages: English
• ISSNs: 1442-6404

Abstract

Abstract: Background: To compare real‐world 24‐month outcomes of phacoemulsification combined with either iStent inject or Hydrus Microstent. Methods: Analysis of data from the Fight Glaucoma Blindness (FGB) international registry. Anonymized data from 344 eyes with mild‐to‐moderate open‐angle glaucoma, normal‐tension glaucoma or ocular hypertension that underwent phacoemulsification combined with either iStent inject (224) or Hydrus Microstent (120) were included. Data were adjusted for baseline characteristics using linear regression and propensity score matching. The primary endpoint was a comparison of mean intraocular pressure (IOP) at 24 months. Results: At 24 months, there was no significant difference in IOP reduction between the two groups, consistent across all analyses. The matched cohort showed iStent inject achieved 3.1 mmHg reduction and Hydrus a 2.3 mmHg reduction ( p = 0.530) and a mean medication reduction of 1.0 for iStent inject versus 0.5 for Hydrus ( p = 0.081). 5.4% of eyes in the iStent inject group and 7.5% of eyes in the Hydrus group required subsequent procedures to improve IOP control within 24 months. Complications were rare with no significant differences between the groups. Conclusions: Twenty‐four‐month outcomes showed sustained IOP reduction with a good safety profile for both groups. There was no significant difference in IOP outcomes between the groups. There may be a small additional reduction in glaucoma medication usage following cataract surgery with iStent inject compared to Hydrus.